Fabio Bove

LLMsFold designs and validates new small molecules targeting pathogenic proteins using LLMs and biophysical simulations, showing strong in silico binding and drug-like profiles.

The paper identifies miRNA copy number variations as a marker for cancer predisposition across species, showing they can distinguish cancer-prone from cancer-resistant organisms.